The G-FINDER project tracks annual investment into R&D for new products and technologies to address priority global health challenges. This includes funding for basic research and the development of new drugs, vaccines, diagnostics and other tools for global health priorities that disproportionately affect people in low- and middle-income countries, such as neglected diseases, emerging infectious diseases, and sexual and reproductive health issues.
The basis of this project is an annual survey of the world’s funders and developers of global health R&D. The G-FINDER survey and report series was founded and created by Policy Cures, and has been funded since its inception by the Bill & Melinda Gates Foundation.
The data collected in this survey has been used to create a unique repository of investment data, providing an unmatched resource for policy-makers, donors, researchers and industry. The database outlines the long-term landscape of funding for R&D for global health priority areas, including where funding gaps exist and how single investments fit into the global picture.
Our unique database of R&D investment data for global health issues can be freely accessed through the G-FINDER data portal. This includes data from both Policy Cures (2007-2015) and Policy Cures Research (2015 onwards).
Our analysis and reports based on this data can be found here.
Analysis and reports from 2008-2015 are available on the Policy Cures website here.
G-FINDER is recognised as the gold standard in tracking and reporting global funding for neglected disease R&D. The WHO Expert Panel’s Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA) includes a recommendation for Member States to commit to providing information to G-FINDER, and G-FINDER has been included – as both a primary source and an indicator – in agenda items presented at the WHO Executive Board meeting and World Health Assembly. G-FINDER is the primary source of neglected disease R&D funding data for both the WHO Global Observatory on Health R&D and Donor Tracker, and helps support the work of many other groups in the broader global health community.
The G-FINDER project started tracking funding data for neglected diseases in 2008 (collecting FY2007 data), emerging infectious diseases in 2015 (collecting FY2014 data), and sexual & reproductive health issues in 2019 (collecting FY2018 data). An overview of how each of these global health issues is defined can be found here.
The purpose of G-FINDER is to track and analyse global investment in the research and development of new health technologies for global health issues. G-FINDER does not, and is not intended to, capture investment in the entire spectrum of global health research. Many research activities that are extremely important for global health are excluded from this project because they are not related to the development of new tools for the diseases included in our scope.
Research activities that are NOT included in the scope of G-FINDER include:
- health systems and operations / implementation research (for example, research into health systems or policy issues, or research into the programmatic delivery of non-product interventions, or existing health technologies), and
- sociological, behavioural and epidemiological research not related to the development of new health technologies.
We also generally exclude investment into non-pharmaceutical tools, for example the development of untreated bed nets. General therapies such as painkillers or nutritional supplements are also excluded, as these investments cannot be ring-fenced to use in low- and middle-income countries only. Investment that is not research-related is similarly excluded: although we recognise the vital importance of activities such as health programme delivery, advocacy, routine disease surveillance programmes, community education and general capacity building to address global health issues, investment in these activities falls outside the scope of G-FINDER.
Please find a list of scope documents for previous surveys here:
- 2022: neglected diseases, emerging infectious diseases, sexual & reproductive health
- 2021: neglected diseases, emerging infectious diseases, sexual & reproductive health
- 2020: neglected diseases, emerging infectious diseases, sexual & reproductive health
- 2019: neglected diseases, emerging infectious diseases, sexual & reproductive health
- 2018: neglected diseases, emerging infectious diseases
- 2017: neglected diseases, emerging infectious diseases
- 2016: neglected diseases
Funding data on R&D investment for global health is collected in a global annual survey run by Policy Cures Research with funding from the Bill & Melinda Gates Foundation.
Identification of survey participants
The G-FINDER project aims to survey all key public, private and philanthropic organisations involved in R&D for global health. Although the primary focus is on funders, we also survey key research, intermediary and industry groups to allow us to better track funding flows.
In 2008 (the first year of the project, then focused exclusively on neglected diseases), survey participants were identified through various avenues, including: our own database of contacts; previous surveys covering HIV/AIDS, tuberculosis, and malaria R&D; and research to find previously unknown funding organisations in countries with high R&D expenditure as a percentage of gross domestic product. In the following year we focused on groups and countries that were missing or poorly represented in 2008, developing proactive strategies to both increase the number of survey participants and improve response rates in these areas. Major Indian public agencies involved in funding R&D for neglected diseases were identified and incorporated in our list of participants, and additional diagnostics organisations and small pharmaceutical and biotechnology firms were also included.
Since then we put in place a number of targeted strategies to further increase survey participation of major public funders and product developers in low- and middle-income countries, including those in South America, Africa and Asia. In addition, each time that a new disease or health issue is added to the survey scope, organisations known to be active in these areas are identified and surveyed.
The G-FINDER project operates according to two key principles:
- capturing and analysing data in a manner that is consistent and comparable across all funders and diseases; and
- presenting funding data that is as close as possible to ‘real’ investment figures.
G-FINDER was originally designed as an online survey. An online survey platform was developed to capture grant data and is still used by the majority of survey participants. An offline grant-based reporting tool is also available. Industry (pharmaceutical companies and biotechnology firms) investment in R&D is not grant-based, so the reporting tool has been tailored for these participants. Instead of grants, companies enter the number of staff working on global health programmes, their salaries, and direct project costs related to these programmes. Companies are required to exclude ‘soft’ figures such as in-kind contributions and costs of capital.
For some organisations with very large datasets, the online survey and equivalent offline reporting tool are difficult to use. The G-FINDER team therefore uses publicly available databases to identify the relevant funding. For the Biomedical Advanced Research and Development Authority (BARDA), funding information is identified using the international and domestic ‘Project Maps’ retrieved from the Medical Countermeasures website. Information on funding from the US Department of Defense (DOD) is collected using the Defense Technical Information Center’s ‘DOD investment budget search’ tool. Funding from the European Commission (EC) is retrieved from the Community Research and Development Information Service (CORDIS) public database and the Innovative Medicines Initiative’s (IMI) online project list. Supplementary data is provided by the EC. Information about R&D projects funded by Innovate UK is extracted from spreadsheets available on its website. In 2019, funding data for the National Natural Science Foundation of China was extracted from its public Chinese-language database for the first time. For the US National Institutes of Health (NIH), grants are collected using the Research Portfolio Online Reporting Tools (RePORTER) and the Research, Condition and Disease Categorization (RCDC) databases.
All participating organisations are asked to only include disbursements (or receipts), rather than commitments made but not yet disbursed. In general, only primary grant data is accepted; the only exception is in the case of data collection collaborations between G-FINDER and other R&D funding surveys, such as the Resource Tracking for HIV Prevention Research & Development Working Group. Data from all sources is subject to verification using the same processes and inclusion criteria.
Survey participants – funders, intermediaries and product developers – are asked to enter grant-by-grant expenditures incurred or disbursements received during their financial year with the largest overlap with the previous calendar year (which is different from the financial year in many countries). Survey participants are asked to enter details of every global health investment they disbursed or received, including:
- a specific disease or health issue, from a predefined list
- a product type (e.g. drugs, vaccines, microbicides), from a predefined list
- an R&D stage within the product type (e.g. discovery and pre-clinical, clinical development, Phase IV/pharmacovigilance studies of new products), from a predefined list
- the name of the funder or recipient of the grant
- a brief description of the grant
- an internal grant identification number
- the grant amount
Where survey participants cannot provide data to this level of detail, they are asked to provide the finest possible level of granularity. Where survey participants are not able to allocate the grant to a single disease, five options are available:
- ‘Core funding of a multi-disease / issue organisation’ such as funding to an organisation working in multiple diseases or sexual & reproductive health issues, where the expenditure per health issue was not known to the funder
- ‘Platform technologies’, further allocated as investment into diagnostic platforms; adjuvants and immunomodulators; or delivery technology and device platforms. These categories capture investments into technologies which were not yet directed towards a specific disease or product
- ‘Multi-disease vector control products’, which captures funding for vector control product R&D that is not yet targeted at a specific disease, or that is targeted at multiple vector-borne diseases
- ‘Multi-purpose prevention technologies’ which target more than one sexual & reproductive health issue
- ‘Unspecified R&D’ for any grants that still cannot be allocated to any of the above categories
All grants reported in the G-FINDER survey are verified against the inclusion criteria. Cross-checking of grants reported by funders and recipients is then conducted using automated reconciliation reports – which match investments reported as disbursed by funders with investments reported as received by intermediaries and product developers – followed by manual grant-level review. Any discrepancies are resolved by contacting both groups. For grants from the US NIH, funding data is supplemented and cross-referenced with information received from the Office of AIDS Research (OAR) and the National Institute of Allergy and Infectious Diseases (NIAID).
Industry figures are reviewed against industry portfolio information held by Policy Cures Research and against full-time equivalent (FTE) and direct costs provided by other companies. Costs that fall outside the expected range, for example, above average FTE costs for clinical staff, are queried with the company and corrected.
All pharmaceutical industry funding data is aggregated and anonymised to protect respondents’ confidentiality. Rather than being attributed to individual companies, pharmaceutical company investment is instead reported according to the type of company, with a distinction made between multinational pharmaceutical companies (MNCs) and small pharmaceutical and biotechnology firms (SMEs).
All funding data we collect is adjusted for inflation and converted to US dollars for the relevant financial year to eliminate artefactual effects caused by inflation and exchange rate fluctuations, allowing accurate comparison of year-on-year changes. Due to these adjustments, historical funding data in tables and figures in the G-FINDER data portal and our most recent reports will differ from data published in older reports.
All reported data is adjusted for inflation using consumer price index (CPI) estimates from the International Monetary Fund (IMF) and any data entered by survey participants in their local currency is converted to USD based on the average annual exchange rate of the relevant financial year as reported by the IMF, Bank of England, United Nations Treasury and OANDA. The G-FINDER data portal also allows all data to be converted to Euros (EUR) or British pound sterling (GBP).
Annual changes in survey participation
While survey participation from the major funders has stabilised over the history of the G-FINDER survey, there remains significant annual variation in survey participation, as a result of survey dropout, increased response from long-term funders and entry of new players in the global health sector. The net effect of these changes is typically relatively small, other than between 2007 and 2008 (the first and second survey years). However, care should be taken in interpreting apparent changes in funding, which may, in some cases, have been contributed to by the artefactual effects of changes in survey participation. Detailed analysis of these changes and their effects is provided by the G-FINDER reports for the relevant year.
Variation between surveys
Other groups also publish annual surveys of global R&D investment into selected global health areas, such as HIV/AIDS and TB. Although we work in close collaboration with some of these groups, both to ease survey fatigue on the part of participants and to clarify any major variance in our findings, each survey nevertheless has slightly different figures. This is chiefly due to differences in scope, in particular inclusion in other surveys of funding for advocacy, capacity building and operational studies – all excluded from G-FINDER. Methodological differences also lead to variations, particularly the adjustment of G-FINDER figures for inflation and exchange rates, which is not always the case for other surveys. As noted above, classification of some funding as ‘unspecified’ in G-FINDER (e.g. multi-disease/multi-issue programmes) may in some cases also lead to different figures than those published in disease/issue-specific surveys.
While the survey methodology has been refined over the past decade, there are limitations to the data presented, including survey non-completion, time lags in the funding process, an inability to disaggregate some investments, and non-comparable or missing data.
Some global health R&D funding may not be captured because organisations are not identified as active in this field and are therefore not invited to participate, or because organisations are invited to participate, but do not respond. Despite this, we are confident that the majority of neglected disease, emerging infectious disease, and sexual & reproductive health R&D funding is captured by G-FINDER, because large funders active in this area and target groups identified by our Advisory Committee are typically responsive and, where they are not, are prioritised during survey follow-up.
Time lags in the funding process
Time lags exist between disbursement and receipt of funding, as well as between receipt of funds and the moment they are actually spent. Thus, grants by funders will not always be recorded as received by recipients in the same financial year, and there may be a delay between R&D investments as reported by G-FINDER and actual expenditure on R&D programmes by product developers and researchers. Nevertheless, as most of our reports analyse trends over an extended period, the impact of time lags is minimal.
Inability to disaggregate investments
A small proportion of funding (now typically well less than 3%) is reported to the survey each year as ‘unspecified’, usually for multi-disease/multi-issue programmes where investment cannot easily be apportioned by disease or issue. A proportion of funding for some health issues is also ‘unspecified’, for instance, when funders report a grant for research into TB basic research and drugs without apportioning funding to each product category. This means that reported funding for some diseases or issues and products will be slightly lower than actual funding, with the difference being included as ‘unspecified’ funding.
Another small, though increasing, fraction (to date always less than 10%) of global funding is given as core funding to R&D organisations that work in multiple health areas, for example, the European and Developing Countries Clinical Trials Partnership (EDCTP) and the Coalition for Epidemic Preparedness Innovations (CEPI). As this funding cannot accurately be allocated by disease or health issue, it is reported as unallocated core funding. In cases where grants to a multi-disease or multi-issue organisation are earmarked for a specific health area or product, they are included under the specific disease/issue-product area.
Due to a significant increase in the size of survey participation in 2009 (when we collected FY2008 data), data from 2008 (when we collected FY2007 data) is the least comparable to other years. Furthermore, the current public official databases for the US NIH data, the RCDC and RePORTER, used for data collection from 2009 onwards, uses a different structure than the US NIH database used in 2008, making this data less comparable. As such, apparent shifts in funding between 2007 and 2008 should be interpreted with caution.
Missing and inaccurate data
G-FINDER can only report the data as it is given to us. Although strenuous efforts are made to check the classification, accuracy and completeness of grants, in a survey of this size it is likely that some data will have been incorrectly entered or that funders may have accidentally omitted some grants. We periodically make amendments to historical G-FINDER data after the publication of a report if better data is provided or errors are identified, which take immediate effect on the G-FINDER data portal. We believe that the checks and balances built into the G-FINDER process mean that mistakes, if present, have only a minor overall impact.